SCHEMBL4235247

SCHEMBL4235247

CC(C)n1c(CCN2CCCCC2)nc2cc(C(=O)O)ccc21

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
KDM4E B2RXH2 4/20 0.50
HSD17B10 Q99714 2/20 0.50
NPC1 O15118 1/20 0.50
GLA P06280 1/20 0.50
MAPT P10636 1/20 0.50
HTT P42858 1/20 0.50
RAB9A P51151 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HDAC6 Q9UBN7 2/20 0.49
LMNA P02545 3/20 0.47
ALDH1A1 P00352 2/20 0.47
CYP2D6 P10635 1/20 0.47
PTGER4 P35408 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.43
POLB P06746 1/20 0.43
PAX8 Q06710 1/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4237298 0.84 MEN1 (0.51) MEN1KMT2AKDM4EHSD17B10NPC1
SCHEMBL6169026 0.73 AGTR1 (0.51) MEN1KMT2ANPC1RAB9AHDAC6
SCHEMBL3891661 0.69 KMT2A (0.66) KMT2AHSD17B10HTTSMN1; SMN2HDAC6
SCHEMBL8906502 0.68 HCAR3 (0.53) MEN1KMT2AKDM4EHSD17B10MAPT
SCHEMBL4258690 0.68 HDAC6 (0.53) MEN1KMT2AKDM4EHSD17B10HTT
SCHEMBL9597041 0.68 HDAC6 (0.50) MEN1KMT2AHSD17B10NPC1HTT
SCHEMBL9597035 0.68 HDAC6 (0.50) MEN1KMT2AHSD17B10NPC1HTT
SCHEMBL16166414 0.68 HDAC6 (0.52) MEN1KMT2AKDM4EHSD17B10MAPT
SCHEMBL15618362 0.67 L3MBTL1 (0.48) KMT2AHSD17B10PTGER4L3MBTL1
SCHEMBL17315023 0.67 HDAC6 (0.51) MEN1KMT2AKDM4EHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US claimed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP disclosed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R MEN1 2447/4885KMT2A 3436/4885KDM4E 1604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.